Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.73 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.70 |
| ▸ | CHRNG | P07510 | 2/20 | 0.70 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.70 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.70 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.70 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.70 |
| ▸ | CHRND | Q07001 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996786 | 1.00 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL14607439 | 0.88 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5007320 | 0.88 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8940223 | 0.88 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL15630452 | 0.88 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5007318 | 0.88 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8940225 | 0.88 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6792848 | 0.88 | SLC6A3 (0.72) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7288917 | 0.88 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL5000882 | 0.88 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153870-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2008-06-26 | — | — | US | disclosed |
| US-7291737-B2 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2007-11-06 | — | — | US | disclosed |
| US-7189737-B2 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050197360-A1 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2005-09-08 | — | — | US | disclosed |
| US-6706880-B2 | USED AS IMAGING OR PHARMACEUTICAL AGENTS, IN THE DIAGNOSIS AND THERAPY OF DRUG ADDICTION, DEPRESSION, ANOREXIA AND NEURODEGENERATIVE DISEASES | RESEARCH TRIANGLE INSTITUTE | 2004-03-16 | — | — | US | disclosed |
| US-20030203934-A1 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2003-10-30 | — | — | US | disclosed |
| US-6531483-B1 | Treating psychostimulant abuse, inhibiting action of psychostimulant, inhibiting neurotransmitter re-uptake, treating Parkinson's Disease, treating depression | RESEARCH TRIANGLE INSTITUTE | 2003-03-11 | — | — | US | disclosed |
| US-20030023090-A1 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE | 2003-01-30 | — | — | US | disclosed |
| EP-1079833-A4 | COCAINE RECEPTOR BINDING LIGANDS | RES TRIANGLE INST (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6329520-B1 | USED AS IMAGING OR PHARMACEUTICAL AGENTS, IN THE DIAGNOSIS AND TREATMENT OF DRUG ADDICTION, DEPRESSION, ANOREXIA AND NEURODEGENERATIVE DISEASES OR IN DETERMINING DOSES OF THERAPEUTIC AGENTS THAT OCCUPY MANY RECEPTORS | RESEARCH TRIANGLE INSTITUTE | 2001-12-11 | — | — | US | disclosed |
| EP-1079833-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061023-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5935953-A | TROPANE DERIVATIVES AS INHIBITORS TO REDUCE THE FEEDING OF AND DELAYING THE MATURATION OF THE INSECTS AND PESTS; INHIBITORS OF A PHENYLETHANOLAMINE, E.G.OCTOPAMINE, REUPTAKE TRANSPORTER; PESTICIDES; PESTISTATS; INSECTICIDES | RESEARCH TRIANGLE INSTITUTE (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153870-A1 | COCAINE RECEPTOR BINDING LIGANDS | SLC18A2, SLC6A3, SLC18A3 | SLC6A3 2/4885SLC6A2 4/4885SLC6A4 11/4885 |
| US-20030023090-A1 | Cocaine receptor binding ligands | OPRL1, SLC18A2, SLC6A3 | SLC6A3 3/4885SLC6A2 6/4885SLC6A4 5/4885 |
| US-20050197360-A1 | Cocaine receptor binding ligands | SLC18A2, SLC6A3, SLC18A3 | SLC6A3 2/4885SLC6A2 4/4885SLC6A4 11/4885 |
| US-20030203934-A1 | Cocaine receptor binding ligands | SLC18A2, SLC6A3, SLC18A3 | SLC6A3 2/4885SLC6A2 4/4885SLC6A4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.